Middle East & Africa Obsessive-Compulsive Disorder (OCD) Drugs Market, By Severity (Mild to Moderate, Moderate to Severe), By Sub-Type (Contamination Obsessions with Washing/Cleaning Compulsion, Harm Obsessions With Checking Compulsions, Obsessions Without Visible Compulsions, Symmetry Obsessions with ordering, arranging and counting compulsions, hoarding, others), By Drugs (Antidepressants, Antipsychotics, NMDA Blocker, Others), By Route of Administration (Oral, Parenteral), By Population type (Pediatrics, Adults), By End User (Hospitals, specialty Clinics, Home healthcare, others), By Distribution Channel (Hospital pharmacy, Retail Pharmacy, Online Pharmacy, Others), By Country (South Africa, Saudi Arabia, UAE, Egypt, Kuwait, Israel, Rest of Middle East and Africa).
Market Analysis and Insights: Middle East and Africa Obsessive-Compulsive Disorder (OCD) Drugs Market
Middle East & Africa Obsessive-Compulsive Disorder (OCD) Drugs market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 8.1% in the forecast period of 2021 to 2028 and is expected to reach USD 26.69 million by 2028. Increasing government support for healthcare and rising awareness regarding current and novel OCD drug products are the major drivers which propelled the demand of the market in the forecast period.
Obsessive-compulsive disorder (OCD) refers to an anxiety disorder that is characterized by unreasonable and uncontrollable thoughts and fears leading an individual to perform repetitive behaviours. Obsessive-compulsive disorder is a disorder known to compel a person to get stuck on a particular thought or fear. The developments in the treatment, therapies and novel treatment, and advancements in the anti-anxiety, antipsychotic and antidepressant drugs is expected to provide various other opportunities in the OCD drugs market. However, patent expiry of the patented drugs and introduction of generic version of branded drugs are factors expected to restraint the market growth in the forecast period.
The OCD drugs market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.
Middle East & Africa Obsessive-Compulsive Disorder (OCD) Drugs Market Scope and Market Size
Obsessive-Compulsive Disorder (OCD) Drugs Market is segmented on the basis of severity, subtypes, drugs, route of administration, population, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of severity, the Middle East and Africa obsessive compulsive disorder (OCD) drugs market is segmented into mild to moderate and moderate to severe. In 2021, the moderate to severe segment is dominating the Middle East, and Africa obsessive obsessive-compulsive disorder (OCD) drugs market due to an increase in the cases of prevalence rate of infectious diseases among the population across the globe are predicted to dominate the market.
- On the basis of subtype, the Middle East and Africa obsessive compulsive disorder (OCD) drugs market is segmented into contamination obsessions with washing/cleaning compulsion, harm obsessions with checking compulsions, obsessions without visible compulsions, symmetry obsessions with ordering, arranging, and counting compulsions, hoarding and others. In 2021, contamination obsessions with washing/cleaning compulsion is are dominating the Middle East and Africa obsessive obsessive-compulsive disorder drug market due to developments in the treatment, therapies, and introduction of novel treatments are predicted to dominate the market.
- On the basis of drugs, the Middle East and Africa obsessive compulsive disorder (OCD) drugs market is segmented into antidepressants, antipsychotics, NMDA blocker, and others. Antidepressants is further segmented into selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAS), and others. SSRIs is further segmented into fluvoxamine, fluoxetine, paroxetine, sertraline and others. SNRIs is further segmented into duloxetine, venlafaxine and others. TCAS is further segmented into clomipramine, amitriptyline, imipramine and others. Antipsychotics is further segmented into risperidone, haloperidol, quetiapine, olanzapine, aripiprazole and others. NMDA blocker is further segmented into ketamine, memantine, and others. In 2021, the antidepressants segment is dominating the Middle East and Africa obsessive obsessive-compulsive disorder drug market due to advancements in the anti-anxiety, antipsychotic and antidepressant drugs, and the robust pipelines for the development of newer treatment are predicted to dominate the market.
- On the basis of route of administration, the Middle East and Africa obsessive compulsive disorder (OCD) drugs market is segmented into oral and parenteral. Oral is further segmented into tablets, capsules, and solution. In 2021, the oral segment is dominating the Middle East and Africa obsessive obsessive-compulsive disorder (OCD) drugs market due to novel treatment, and advancements in therapies are predicted to dominate the market.
- On the basis of population, the Middle East and Africa obsessive compulsive disorder (OCD) drugs market is segmented into pediatrics and adults. In 2021, the adults segment is dominating the Middle East and Africa obsessive obsessive-compulsive disorder drug market due to research and development to enhance bioavailability, pharmacology, safety, and dosage parameters is are predicted to dominate the market.
- On the basis of end user, the Middle East and Africa obsessive compulsive disorder (OCD) drugs market is segmented into hospitals, specialty clinics, home healthcare and others. In 2021, the hospitals segment is dominating the Middle East and Africa obsessive obsessive-compulsive disorder drug market due to an increase in the cases of prevalence rate of infectious diseases among the population across the globe is predicted to dominate the market.
- On the basis of distribution channel, the Middle East and Africa obsessive compulsive disorder (OCD) drugs market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and others. In 2021, hospital pharmacy segment is dominating the Middle East and Africa obsessive compulsive disorder drug market due to novel treatment and advancements in the anti-anxiety, antipsychotic and antidepressant drugs are predicted to dominate the market.
- In Middle East and Africa, South Africa is the dominant region due to rising demand for effective therapies and rising awareness about the syndrome.
Obsessive-Compulsive Disorder (OCD) Drugs Market Country Level Analysis
The OCD drugs market is analyzed, and market size information is provided on the basis of severity, subtypes, drugs, route of administration, population, end user, and distribution channel.
The countries covered in the OCD market report are the Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East & Africa.
Antidepressants segment.in Middle East & Africa region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of robust pipelines for development of newer treatment and the growth in awareness regarding the disorder.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East & Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Strategic initiatives by market players and increasing generic approvals are boosting the market growth of OCD drugs market.
Obsessive-Compulsive Disorder (OCD) Drugs market also provides you with detailed market analysis for every country growth in OCD products industry with drugs sales, impact of advancement, technology, and changes in regulatory scenarios with their support for the OCD drugs market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Laxative Market Share Analysis
OCD drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to OCD drugs market.
The major companies operating in the global obsessive-compulsive disorder (OCD) drugs market are Mallinckrodt, , Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Wockhardt, Lupin Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical industries Ltd., Alvogen, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma USA (a subsidiary of Aurobindo Pharma), Par Pharmaceutical, Apotex Inc., Lannett, Abbott, Eli Lilly and Company, Viatria Inc., H. LUNDBECK A/S, GlaxoSmithKline plc., Pfizer Inc., Sebela Pharmaceuticals among others.
Many product launch and agreement are also initiated by the companies’ worldwide, which are also accelerating the OCD drugs market.
For instance,
- In June 2021, Mallinckrodt, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen – dsat) for the treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns).
- In June 2021, Zydus Cadila, an innovation-driven, global healthcare company today announced that it has signed a non-exclusive licensing agreement with Gilead Sciences Inc., for the manufacturing and distribution of Remdesivir, the investigational drug, which has been issued an Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) to treat patients suffering from severe symptoms of Novel Coronavirus. Zydus has been supporting the fight against COVID 19 with therapeutics, vaccines, and diagnostics.
- In August 2020, Wockhardt, the global pharmaceutical and biotechnology major announced that it has entered into an agreement with the UK Government to fill finish COVID-19 vaccines. The manufacturing will be undertaken at CP Pharmaceuticals, a subsidiary of Wockhardt based in Wrexham, North Wales. As per the terms of the agreement the company has reserved manufacturing capacity to allow for the supply of multiple vaccines to the UK Government in its fight against COVID19, including AZD1222, the vaccine co-invented by the University of Oxford and its spinout company, Vaccitech and licensed by AstraZeneca.
Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the OCD drugs market which also provides the benefit for organization to improve their offering for OCD drug products.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 SEVERITY LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
6 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: REGULATIONS
6.1 THE U.S. REGULATORY FRAMEWORK FOR OCD DRUGS
6.2 EUROPE REGULATORY FRAMEWORK FOR OCD DRUGS
6.3 AUSTRALIA REGULATORY GUIDANCE ON OCD DRUGS
7 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: REIMBURSEMENT SCENARIO
8 COST ANALYSIS
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISE IN CLINICAL TRIALS FOR OBSESSIVE-COMPULSIVE DISORDER (OCD)
9.1.2 INCREASING CASES OF OBSESSIVE-COMPULSIVE DISORDER (OCD) WORLDWIDE
9.1.3 INCREASING R&D INVESTMENT BY KEY MARKET PLAYERS
9.1.4 CHANGES IN LIFESTYLE AND ENVIRONMENTAL STRESS AMONG PEOPLE
9.1.5 INCREASING GENERIC APPROVALS
9.2 RESTRAINTS
9.2.1 RECALL OF DRUGS
9.2.2 ADVERSE EFFECTS OF DRUGS
9.2.3 STRINGENT GOVERNMENT REGULATIONS FOR OCD DRUGS DEVELOPMENT
9.2.4 UNAWARENESS AMONG PEOPLE OF EXISTENCE OF OCD
9.3 OPPORTUNITIES
9.3.1 TECHNOLOGICAL ADVANCEMENT FOR THE TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER (OCD)
9.3.2 RISING COLLABORATIONS, AND MERGER & ACQUISITIONS AMONG THE MARKET PLAYERS
9.3.3 RISE IN QUALITY CONCERNS
9.4 CHALLENGES
9.4.1 USE OF ALTERNATIVE THERAPIES
9.4.2 LIMITATIONS OF CURRENT OCD TREATMENT
10 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET
10.1 IMPACT ON PRICE
10.2 IMPACT ON DEMAND
10.3 IMPACT ON SUPPLY CHAIN
10.4 STRATEGIC DECISIONS FOR MANUFACTURERS
10.5 CONCLUSION
11 MARKET BY DRUGS
11.1 TOTAL ADDRESSABLE MARKET
11.2 PATIENT POPULATION (2019-2028)
12 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY
12.1 OVERVIEW
12.2 MODERATE TO SEVERE
12.3 MILD TO MODERATE
13 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE
13.1 OVERVIEW
13.2 CONTAMINATION OBSESSIONS WITH WASHING/CLEANING COMPULSION
13.3 HARM OBSESSIONS WITH CHECKING COMPULSIONS
13.4 OBSESSIONS WITHOUT VISIBLE COMPULSIONS
13.5 SYMMETRY OBSESSIONS WITH ORDERING, ARRANGING, AND COUNTING COMPULSIONS
13.6 HOARDING
13.7 OTHERS
14 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS
14.1 OVERVIEW
14.2 ANTIDEPRESSANTS
14.2.1 SELECTIVE SEROTONIN REUPTAKE INHIBITORS
14.2.1.1 FLUVOXAMINE
14.2.1.2 FLUOXETINE
14.2.1.3 PAROXETINE
14.2.1.4 SERTRALINE
14.2.1.5 OTHERS
14.2.2 SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS
14.2.2.1 DULOXETINE
14.2.2.2 VENLAFAXINE
14.2.2.3 OTHERS
14.2.3 TRICYCLIC ANTIDEPRESSANTS
14.2.3.1 CLOMIPRAMINE
14.2.3.2 AMITRIPTYLINE
14.2.3.3 IMIPRAMINE
14.2.3.4 OTHERS
14.3 ANTIPSYCHOTICS
14.3.1 RISPERIDONE
14.3.2 OLANZAPINE
14.3.3 ARIPIPRAZOLE
14.3.4 QUETIAPINE
14.3.5 HALOPERIDOL
14.3.6 OTHERS
14.4 NMDA BLOCKERS
14.4.1 MEMANTINE
14.4.2 KETAMINE
14.4.3 OTHERS
14.5 OTHERS
15 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.2.1 TABLET
15.2.2 CAPSULE
15.2.3 SOLUTION
15.3 PARENTERAL
16 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION
16.1 OVERVIEW
16.2 ADULTS
16.3 PEDIATRICS
17 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER
17.1 OVERVIEW
17.2 HOSPITALS
17.3 SPECIALTY CLINICS
17.4 HOME HEALTHCARE
17.5 OTHERS
18 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 HOSPITAL PHARMACY
18.3 RETAIL PHARMACY
18.4 ONLINE PHARMACY
18.5 OTHERS
19 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION
19.1 MIDDLE EAST & AFRICA
19.1.1 SOUTH AFRICA
19.1.2 SAUDI ARABIA
19.1.3 UAE
19.1.4 KUWAIT
19.1.5 ISRAEL
19.1.6 EGYPT
19.1.7 REST OF MIDDLE EAST & AFRICA
20 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: COMPANY LANDSCAPE
20.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
21 SWOT ANALYSIS
22 COMPANY PROFILE
22.1 SUN PHARMACEUTICAL INDUSTRIES LTD.
22.1.1 COMPANY SNAPSHOT
22.1.2 REVENUE ANALYSIS
22.1.3 COMPANY SHARE ANALYSIS
22.1.4 PRODUCT PORTFOLIO
22.1.5 RECENT DEVELOPMENTS
22.2 H. LUNDBECK A/S
22.2.1 COMPANY SNAPSHOT
22.2.2 REVENUE ANALYSIS
22.2.3 COMPANY SHARE ANALYSIS
22.2.4 PRODUCT PORTFOLIO
22.2.5 RECENT DEVELOPMENTS
22.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
22.3.1 COMPANY SNAPSHOT
22.3.2 REVENUE ANALYSIS
22.3.3 COMPANY SHARE ANALYSIS
22.3.4 PRODUCT PORTFOLIO
22.3.5 RECENT DEVELOPMENTS
22.4 ELI LILLY AND COMPANY
22.4.1 COMPANY SNAPSHOT
22.4.2 REVENUE ANALYSIS
22.4.3 COMPANY SHARE ANALYSIS
22.4.4 PRODUCT PORTFOLIO
22.4.5 RECENT DEVELOPMENTS
22.5 APOTEX INC.
22.5.1 COMPANY SNAPSHOT
22.5.2 COMPANY SHARE ANALYSIS
22.5.3 PRODUCT PORTFOLIO
22.5.4 RECENT DEVELOPMENTS
22.6 VIATRIS INC.
22.6.1 COMPANY SNAPSHOT
22.6.2 REVENUE ANALYSIS
22.6.3 PRODUCT PORTFOLIO
22.6.4 RECENT DEVELOPMENTS
22.7 LANNETT
22.7.1 COMPANY SNAPSHOT
22.7.2 REVENUE ANALYSIS
22.7.3 PRODUCT PORTFOLIO
22.7.4 RECENT DEVELOPMENTS
22.8 GLAXOSMITHKLINE PLC
22.8.1 COMPANY SNAPSHOT
22.8.2 REVENUE ANALYSIS
22.8.3 PRODUCT PORTFOLIO
22.8.4 RECENT DEVELOPMENT
22.9 ALVOGEN
22.9.1 COMPANY SNAPSHOT
22.9.2 PRODUCT PORTFOLIO
22.9.3 RECENT DEVELOPMENTS
22.1 PFIZER INC.
22.10.1 COMPANY SNAPSHOT
22.10.2 REVENUE ANALYSIS
22.10.3 PRODUCT PORTFOLIO
22.10.4 RECENT DEVELOPMENTS
22.11 AMNEAL PHARMACEUTICALS LLC
22.11.1 COMPANY SNAPSHOT
22.11.2 REVENUE ANALYSIS
22.11.3 PRODUCT PORTFOLIO
22.11.4 RECENT DEVELOPMENTS
22.12 DR.REDDY’S LABORATORIES LTD.
22.12.1 COMPANY SNAPSHOT
22.12.2 REVENUE ANALYSIS
22.12.3 PRODUCT PORTFOLIO
22.12.4 RECENT DEVELOPMENTS
22.13 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA)
22.13.1 COMPANY SNAPSHOT
22.13.2 REVENUE ANALYSIS
22.13.3 PRODUCT PORTFOLIO
22.13.4 RECENT DEVELOPMENTS
22.14 ABBOTT
22.14.1 COMPANY SNAPSHOT
22.14.2 REVENUE ANALYSIS
22.14.3 PRODUCT PORTFOLIO
22.14.4 RECENT DEVELOPMENTS
22.15 LUPIN PHARMACEUTICALS, INC.
22.15.1 COMPANY SNAPSHOT
22.15.2 REVENUE ANALYSIS
22.15.3 PRODUCT PORTFOLIO
22.15.4 RECENT DEVELOPMENTS
22.16 MALLINCKRODT
22.16.1 COMPANY SNAPSHOT
22.16.2 REVENUE ANALYSIS
22.16.3 PRODUCT PORTFOLIO
22.16.4 RECENT DEVELOPMENTS
22.17 PAR PHARMACEUTICAL
22.17.1 COMPANY SNAPSHOT
22.17.2 REVENUE ANALYSIS
22.17.3 PRODUCT PORTFOLIO
22.17.4 RECENT DEVELOPMENTS
22.18 SEBELA PHARMACEUTICALS
22.18.1 COMPANY SNAPSHOT
22.18.2 PRODUCT PORTFOLIO
22.18.3 RECENT DEVELOPMENT
22.19 ZYDUS PHARMACEUTICALS USA INC. (A SUBSIDIARY OF ZYDUS CADILA)
22.19.1 COMPANY SNAPSHOT
22.19.2 REVENUE ANALYSIS
22.19.3 PRODUCT PORTFOLIO
22.19.4 RECENT DEVELOPMENTS
22.2 WOCKHARDT
22.20.1 COMPANY SNAPSHOT
22.20.2 REVENUE ANALYSIS
22.20.3 PRODUCT PORTFOLIO
22.20.4 RECENT DEVELOPMENTS
23 QUESTIONNAIRE
24 RELATED REPORTS
List of Table
LIST OF TABLES
TABLE 1 BELOW MENTIONED ARE THE COST OF OCD DRUGS, AVAILABLE IN DIFFERENT DOSAGE FORMS SUCH AS A TABLET, CAPSULE, PARENTAL, AND STRENGTHS USED MIDDLE EAST AND AFRICALY TO TREAT OBSESSIVE-COMPULSIVE DISORDER.
TABLE 2 DRUGS UNDER INVESTIGATIONS FOR OCD
TABLE 3 R&D COST BY KEY MARKET PLAYERS (USD MILLIONS) (2020)
TABLE 4 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA MODERATE TO SEVERE IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA MILD TO MODERATE IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUB TYPE 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA CONTAMINATION OBSESSIONS WITH WASHING/CLEANING COMPULSION IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA HARM OBSESSIONS WITH CHECKING COMPULSIONS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA OBSESSIONS WITHOUT VISIBLE COMPULSIONS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA SYMMETRY OBSESSIONS WITH ORDERING, ARRANGING, AND COUNTING COMPULSIONS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA HOARDING IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA TRICYCLIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA PARENTERAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA ADULTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA PEDIATRICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA HOSPITALS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN OBSESSIVE-COMPULSIVE (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA ONLINE PHARMACY IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 57 SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 58 SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 59 SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 60 SOUTH AFRICA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 61 SOUTH AFRICA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 62 SOUTH AFRICA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 63 SOUTH AFRICA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 64 SOUTH AFRICA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 65 SOUTH AFRICA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 66 SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 67 SOUTH AFRICA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 68 SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 69 SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 70 SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 71 SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 72 SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 73 SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 74 SAUDI ARABIA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 75 SAUDI ARABIA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 76 SAUDI ARABIA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 77 SAUDI ARABIA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 78 SAUDI ARABIA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 79 SAUDI ARABIA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 80 SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 81 SAUDI ARABIA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 82 SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 83 SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 84 SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 85 UAE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 86 UAE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 87 UAE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 88 UAE ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 89 UAE SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 90 UAE SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 91 UAE TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 92 UAE ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 93 UAE NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 94 UAE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 95 UAE ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 UAE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 97 UAE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 98 UAE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 99 KUWAIT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 100 KUWAIT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 101 KUWAIT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 102 KUWAIT ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 103 KUWAIT SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 104 KUWAIT SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 105 KUWAIT TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 106 KUWAIT ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 107 KUWAIT NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 108 KUWAIT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 109 KUWAIT ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 110 KUWAIT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 111 KUWAIT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 112 KUWAIT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 113 ISRAEL OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 114 ISRAEL OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 115 ISRAEL OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 116 ISRAEL ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 117 ISRAEL SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 118 ISRAEL SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 119 ISRAEL TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 120 ISRAEL ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 121 ISRAEL NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 122 ISRAEL OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 123 ISRAEL ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 124 ISRAEL OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 125 ISRAEL OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 126 ISRAEL OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 127 EGYPT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 128 EGYPT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 129 EGYPT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 130 EGYPT ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 131 EGYPT SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 132 EGYPT SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 133 EGYPT TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 134 EGYPT ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 135 EGYPT NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 136 EGYPT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 137 EGYPT ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 138 EGYPT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 139 EGYPT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 140 EGYPT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 141 REST OF MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
List of Figure
LIST OF FIGURES
FIGURE 1 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET : MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET MARKET APPLICATION COVERAGE GRID
FIGURE 9 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET SEGMENTATION
FIGURE 11 RISE IN CLINICAL TRIALS FOR OBSESSIVE-COMPULSIVE DISORDER AND INCREASING R&D INVESTMENT BY KEY MARKET PLAYERS ARE EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 SEVERITY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUG MARKET IN 2021 & 2028
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES ABD CHALLENGES OF MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET
FIGURE 14 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SEVERITY, 2020
FIGURE 15 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SEVERITY, 2020-2028 (USD MILLION)
FIGURE 16 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SEVERITY, CAGR (2021-2028)
FIGURE 17 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DIOSRDER (OCD) DRUG MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 18 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SUBTYPE, 2020
FIGURE 19 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SUBTYPE, 2020-2028 (USD MILLION)
FIGURE 20 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SUBTYPE, CAGR (2020-2028)
FIGURE 21 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SUBTYPE, LIFELINE CURVE
FIGURE 22 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DRUGS, 2020
FIGURE 23 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DRUGS, 2020-2028 (USD MILLION)
FIGURE 24 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DRUGS, CAGR (2020-2028)
FIGURE 25 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DRUGS, LIFELINE CURVE
FIGURE 26 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 27 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 28 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)
FIGURE 29 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 30 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY POPULATION, 2020
FIGURE 31 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY POPULATION, 2020-2028 (USD MILLION)
FIGURE 32 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY POPULATION, CAGR (2021-2028)
FIGURE 33 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY, LIFELINE CURVE
FIGURE 34 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY END USER, 2020
FIGURE 35 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 36 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY END USER, CAGR (2021-2028)
FIGURE 37 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 39 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 40 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 41 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: SNAPSHOT (2020)
FIGURE 43 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY COUNTRY (2020)
FIGURE 44 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY COUNTRY (2021 & 2028)
FIGURE 45 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY COUNTRY (2020 & 2028)
FIGURE 46 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SEVERITY (2021 & 2028)
FIGURE 47 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: COMPANY SHARE 2020 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
